Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 trial of SGN-CD33A as monotherapy in patients with CD33-positive acute myeloid leukemia (AML)
    Meeting Abstract

    Stein, A. S.; Walter, R. B.; Erba, H. P.; Fathi, A. T.; Advani, A. S.; Lancet, J. E.; Ravandi, F.; Kovacsovics, T. J.; DeAngelo, D. J.; Bixby, D.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: Results of a phase 1/2 trial
    Meeting Abstract

    Stein, E. M.; DiNardo, C.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Kantarjian, H. M.; Sekeres, M. A.; Fathi, A. T.; Flinn, I. W.; Frankel, A. E.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance])
    Meeting Abstract

    Stone, R. M.; Mandrekar, S.; Sanford, B. L.; Geyer, S.; Bloomfield, C. D.; Dohner, K.; Thiede, C.; Marcucci, G.; Lo-Coco, F.; Klisovic, R. B.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Integrated DNA/RNA profiling for somatic alterations in adult B-cell ALL
    Meeting Abstract

    Rapaport, F.; Patel, J.; He, J.; Brennan, T. A.; Nahas, M.; Balassubramanian, S.; Otto, G.; Lipson, D.; Stephens, P.; Miller, V. A.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Multi-center US intergroup study of intensive chemotherapy plus dasatinib followed by allogeneic stem cell transplant in patients with Philadelphia chromosome positive acute lymphoblastic leukemia younger than 60
    Meeting Abstract

    Ravandi, F.; Othus, M.; O'Brien, S.; Forman, S. J.; Ha, C. S.; Wong, J. Y. C.; Tallman, M. S.; Paietta, E.; Racevskis, J.; Uy, G. L.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) with the T315I mutation
    Meeting Abstract

    Nicolini, F. E.; Basak, G. W.; Kim, D. W.; Olavarria, E.; Pinilla-Ibarz, J.; Apperley, J. F.; Hughes, T. P.; Niederwieser, D.; Mauro, M. J.; Chuah, C.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single- agent activity in a phase I study of patients with CML with failure of prior TKI therapy
    Meeting Abstract

    Ottmann, O. G.; Alimena, G.; DeAngelo, D. J.; Goh, Y. T.; Heinrich, M. C.; Hochhaus, A.; Hughes, T. P.; Mahon, F. X.; Mauro, M. J.; Minami, H.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Diverse mechanisms of vemurafenib resistance in BRAF-mutant hairy cell leukemia
    Meeting Abstract

    Park, J. H.; Chung, S. S.; Durham, B.; Chung, Y. R.; Scott, S.; Getta, B.; Kim, E.; Saven, A.; Stone, R. M.; Rai, K. R.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Effects of obesity on the efficacy and toxicity of induction chemotherapy in adult acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Peterson, T. J.; Lin, A.; Hilden, P.; Devlin, S.; Adel, N. G.; Park, J. H.
    Blood (2015)

    Fulltext@MSK | Save